Utilizing propensity score matching methodology to assess the impact of adjuvant radiotherapy on the prognosis of men diagnosed with breast cancer

Author:

Meng Jing1,Wu Qi2,Wang Jianlin3,Zhao Aimei4,Ren Huiwen3,Sun Zhiqiang3,Luo Judong3

Affiliation:

1. Graduate School of Dalian Medical University

2. Heze Medical College

3. The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Nanjing Medical University

4. Dongchangfu Maternal and Child Health Hospital of Liaocheng

Abstract

Abstract Background Male breast cancer (MBC) is a rare condition, and the effectiveness of radiotherapy in treating MBC patients remains uncertain. This study aimed to investigate the role of adjuvant radiotherapy (RT) in the management of MBC. Methods MBC patients from the Surveillance Epidemiology and End Results (SEER) database were included in the study and were divided into RT and no-RT groups. A 1:1 propensity score matching (PSM) method was employed to balance baseline characteristics. Kaplan-Meier curves were used to evaluate the impact of RT on overall survival (OS) and breast cancer-specific survival (BCSS). Cox analyses were conducted to identify factors associated with survival. Subgroup analysis was performed to identify subgroups of MBC patients who might benefit from RT. Results In the matched cohort, the 5-year OS and BCSS rates were higher in the RT group compared to the no-RT group (p = 0.023, p = 0.035). Univariate and multivariate analysis demonstrated significant differences in both OS and BCSS associated with RT (p = 0.024, p = 0.037, p = 0.025, p = 0.028). Forest plots revealed a greater OS benefit in patients with T1 stage, age ≥ 60 years, estrogen receptor positivity (ER+), absence of distant metastasis (M0), married status, and with local or regional metastases. Furthermore, a greater BCSS benefit was observed in patients aged ≥ 60 years, ER+, progesterone receptor negativity (PR-), M0, married status, and with regional metastases who received RT for MBC. Conclusion RT in MBC patients is associated with improved survival and is recommended for patients aged ≥ 60 years with ER+, PR-, M0, married status, and regional metastases.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3